Highlights from the 15th International Symposium on MDS

Clinical Trials of the Combination of Hypomethylating Agents with Immune Checkpoint Inhibitors in Patients with MDS Guillermo Garcia-Manero, MD Begin

High-Risk MDS: What’s After Aza? Jean-Pierre Issa, MD Begin

SGI-110 plus Atezolizumab in Relapsed/Refractory MDS Casey O’Connell, MD, FACP Begin

Bridging the Canyon Between Myelodysplastic Syndromes Discovery and MDS Therapy David P. Steensma, MD, FACP Begin